Triad Wealth Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.19M Buy
4,485
+179
+4% +$211K 0.29% 56
2026
Q2
$4.83M Sell
4,306
-30
-0.7% -$30.7K 0.28% 65
2026
Q1
$3.25M Buy
4,336
+1,838
+74% +$1.86M 0.26% 74
2025
Q4
$2.68M Buy
2,498
+1,335
+115% +$1.28M 0.26% 76
2025
Q3
$887K Sell
1,163
-222
-16% -$165K 0.11% 130
2025
Q2
$1.08M Buy
1,385
+419
+43% +$326K 0.22% 79
2025
Q1
$798K Buy
966
+114
+13% +$94.9K 0.25% 69
2024
Q4
$658K Buy
+852
New +$705K 0.24% 73
2024
Q3
– Sell
-614
Closed -$556K – 529
2024
Q2
$556K Buy
614
+205
+50% +$164K 0.29% 33
2024
Q1
$318K Buy
+409
New +$291K 0.24% 40

Other funds holding LLY

Triad Wealth Partners's LLY Position: Q3 2026 in Review

Triad Wealth Partners increased its Eli Lilly (LLY) stake by 4.2% in Q3 2026, buying an estimated $211K and bringing the position to 4,485 shares worth $5.19M. The position accounts for 0.29% of the portfolio, ranked #56.

Triad Wealth Partners first reported a position in LLY in Q1 2024 and has held it in 10 quarters since. 4,626 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Triad Wealth Partners held 4,485 shares of Eli Lilly worth $5.19M as of Q3 2026.
  • Triad Wealth Partners bought 179 Eli Lilly shares in Q3 2026, an estimated $211K.
  • Eli Lilly made up 0.29% of Triad Wealth Partners's portfolio in Q3 2026, its #56 holding.
  • Triad Wealth Partners first reported a position in Eli Lilly in Q1 2024 and has held it in 10 quarters since.
  • 4,626 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Triad Wealth Partners's 13F filing for Q3 2026, filed 26 Oct 2026.